The efficacy of administering elbasvir/grazoprevir as hepatitis C therapy in hemodialysis patients with comorbid of hypertension and diabetes mellitus

Syifa Mustika; Yhang Lidi Tama; Zuhrotus Sholichah

doi:10.36216/jpd.v7i2.228

Authors

Syifa Mustika Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia
Yhang Lidi Tama Internal Medicine Resident, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia
Zuhrotus Sholichah Internal Medicine Resident, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia

DOI:

https://doi.org/10.36216/jpd.v7i2.228

Keywords:

Hepatitis C, Hypertension, Diabetes, Hemodialysis, SVR

Abstract

Background: Hepatitis C and chronic kidney disease (CKD) are significant global health burdens. Hemodialysis therapy can pose a risk of hepatitis C infection. Conditions related to Hepatitis C, such as hypertension and diabetes, have morbidity and mortality rates and can impact the outcomes of hepatitis C treatment.

Objective: This study aimed to assess the efficacy of Elbasvir/Grazoprevir as hepatitis C therapy in hemodialysis patients with comorbid hypertension and diabetes mellitus.

Methods: The target population for this study consists of hepatitis C-infected patients undergoing routine hemodialysis with comorbid hypertension and diabetes mellitus who were treated with Elbasvir/Grazoprevir. The data collected included demographic characteristics, comorbid conditions (hypertension and diabetes mellitus), cirrhosis status, and whether patients achieved Sustained Virologic Response (SVR). Multinomial logistic regression was used to calculate the odds ratio (OR).

Results: From the population profile of the study, a total of 164 individuals were included, with the majority being under 60 years old. Patients with comorbid hypertension or diabetes mellitus achieved SVR rates of 95% and 83.3%, respectively, while patients with both comorbid conditions, hypertension, and diabetes mellitus, had an SVR rate of 74.07%. The multinomial logistic regression analysis showed that patients with both comorbid conditions (HT and DM) had a higher risk of failing to achieve SVR compared to patients without comorbid conditions, with an OR of 22.4, p = 0.005.

Conclusion: Administering Elbasvir/Grazoprevir for hepatitis C therapy in hemodialysis patients with comorbid hypertension and/or diabetes mellitus carries a higher risk of SVR failure compared to those without comorbid conditions.

Downloads

Download data is not yet available.

Author Biographies

Syifa Mustika, Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia

Gastroenterohepatology Division, Department of Internal Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia
Yhang Lidi Tama, Internal Medicine Resident, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia

Internal Medicine Resident, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia
Zuhrotus Sholichah, Internal Medicine Resident, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia

Internal Medicine Resident, Faculty of Medicine, Brawijaya University, Malang, East Java, Indonesia

References

Iliescu EL, Mercan-Stanciu A, Toma L. Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrol. 2020;21(1):21.

O'Donnell A, Pham N, Battisti L, et al. Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection. PLoS One. 2022;17(5):e0268478.

Nguyen DB, Bixler D, Patel PR. Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention. Semin Dial. 2019;32(2):127-134.

Drazilova S, Gazda J, Janicko M, et al. Chronic hepatitis C association with diabetes mellitus and cardiovascular risk in the era of DAA therapy. Can J Gastroenterol Hepatol. 2018:6150861.

Butt AA, Ren Y, Puenpatom A, et al. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: An ERCHIVES study. Aliment Pharmacol Ther. 2018;48(1):35–43.

Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol. 2015;7(1):78–92.

Awadallah H, Mortada A, Al-Shaff RE, et al. The association between systemic hypertension and chronic HCV-4 Infection. Cardiol Cardiovasc Res. 2017;1(2):32–38.

Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?. J Viral Hepat. 2019;19(9):601–607.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;109:1–99.

Goodkin DA, Bieber B, Gillespie B, et al. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38(5):405–412.

El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to therapy. World J Gastroenterol. 2009;15(40):4993-4999.